Journal
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.734720
Keywords
extracellular vesicle therapeutics; drug and vector delivery; exosome-based therapeutics; nanomedicine; nanovesicles; microparticles; EV hybrids and mimetics; bioengineering; clincal trials and utility
Categories
Funding
- National Health and Medical Research Council [1139489, 1057741]
- Helen Amelia Hains Fellowship
- Victorian Government's Operational Infrastructure Support Program
- Australian Government Training Program (RTP) scholarship
- Baker Institute Bright Sparks Scholarship Top Up
- joint Baker Institute-La Trobe University Research Training Program scholarships
Ask authors/readers for more resources
Although EVs show great promise as therapeutic modalities due to their endogenous characteristics, further bioengineering refinement is needed to overcome clinical and commercial limitations. Clinical applications of EV-based therapeutics are diverse, including immunomodulation, tissue regeneration, and delivery vectors for combination therapies. Technologies such as imaging, quantitative analyses, and use of biocompatible natural sources for producing EVs will play a key role in overcoming limitations and advancing the field.
Extracellular vesicles (EVs) hold great promise as therapeutic modalities due to their endogenous characteristics, however, further bioengineering refinement is required to address clinical and commercial limitations. Clinical applications of EV-based therapeutics are being trialed in immunomodulation, tissue regeneration and recovery, and as delivery vectors for combination therapies. Native/biological EVs possess diverse endogenous properties that offer stability and facilitate crossing of biological barriers for delivery of molecular cargo to cells, acting as a form of intercellular communication to regulate function and phenotype. Moreover, EVs are important components of paracrine signaling in stem/progenitor cell-based therapies, are employed as standalone therapies, and can be used as a drug delivery system. Despite remarkable utility of native/biological EVs, they can be improved using bio/engineering approaches to further therapeutic potential. EVs can be engineered to harbor specific pharmaceutical content, enhance their stability, and modify surface epitopes for improved tropism and targeting to cells and tissues in vivo. Limitations currently challenging the full realization of their therapeutic utility include scalability and standardization of generation, molecular characterization for design and regulation, therapeutic potency assessment, and targeted delivery. The fields' utilization of advanced technologies (imaging, quantitative analyses, multi-omics, labeling/live-cell reporters), and utility of biocompatible natural sources for producing EVs (plants, bacteria, milk) will play an important role in overcoming these limitations. Advancements in EV engineering methodologies and design will facilitate the development of EV-based therapeutics, revolutionizing the current pharmaceutical landscape.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available